Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study

Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31.

¹ Vejle Hospital and University of Southern Denmark, Vejle, Denmark.
² Sarah Cannon Research Institute, University College London Cancer Institute, London, United Kingdom.
³ Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
⁴ Department of Hematology, UMC Utrecht Cancer Centre, Utrecht, The Netherlands.
⁵ Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
⁶ Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom.
⁷ Hematology Department, University Hospital, Vandoeuvre Les Nancy, France.
⁸ The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁹ Genmab US Inc., Princeton, NJ, USA.
¹⁰ Janssen Biologics, Leiden, The Netherlands.
¹¹ Janssen Research & Development, Shanghai, China.
¹² Janssen Research & Development, Spring House, PA, USA.
¹³ Janssen Research & Development, Raritan, NJ, USA.

No abstract available

Keywords: daratumumab; monoclonal antibody; multiple myeloma; plasma cell disorders; relapsed/refractory multiple myeloma.

Publication types